Subsequent trials have since tested the dual mIDH1/2 inhibitor vorasidenib34, which is more CNS-penetrant and exhibits a significantly higher tumor:plasma ratio in IDH-mutant glioma patients compared to ivosidenib (1.69 vs. 0.10)35. This evidence concerns the gene IDH2 and central nervous system cancer.